Westra S, Krul-Poel Y H M, van Wijland H J, Ter Wee M M, Stam F, Lips P, Pouwer F, Simsek S
Department of Internal MedicineMedical Centre Alkmaar, Alkmaar, the Netherlands.
Department of General PracticeDIAZON, Alkmaar, the Netherlands.
Endocr Connect. 2016 Nov;5(6):61-69. doi: 10.1530/EC-16-0070. Epub 2016 Nov 1.
Increased levels of depressive symptoms, fatigue or pain (all dimensions of reduced health-related quality of life (HRQOL)) are common in people with type 2 diabetes mellitus (DM). Earlier studies have reported associations between low vitamin D status and fatigue and depressive symptoms. The aim of the present study was to examine the effects of vitamin D supplementation on dimensions of HRQOL in people with type 2 DM.
Randomised, double-blind, placebo-controlled trial.
The effect of monthly cholecalciferol 50,000 IU vs placebo on HRQOL was assessed in 275 adults with type 2 DM derived from general practices. HRQOL at baseline and after six months using the Short Form 36 Health Survey (SF-36) was collected. Linear regression analyses were used to compare the change in HRQOL over time between the vitamin D and placebo group.
187/275 (68%) completed baseline and follow-up SF-36 and were included in the analysis. Median serum 25-hydroxyvitamin D almost doubled in the intervention group compared to that in the placebo group (58.5-106.0 nmol/L vs 60.0-61.5 nmol/L, respectively). A small significant difference (adjusted B: -8.90; 95% CI: -17.16 to -0.65) between both groups was seen concerning the SF-36 domain role limitations due to physical problems in disadvantage of the vitamin D group.
Six months of vitamin D supplementation did not improve HRQOL in non-vitamin D-deficient people with type 2 DM managed on oral antidiabetic therapy.
抑郁症状、疲劳或疼痛（均为健康相关生活质量（HRQOL）降低的维度）水平升高在2型糖尿病（DM）患者中很常见。早期研究报告了低维生素D状态与疲劳及抑郁症状之间的关联。本研究的目的是探讨补充维生素D对2型DM患者HRQOL各维度的影响。
随机、双盲、安慰剂对照试验。
在来自全科医疗的275名2型DM成年患者中，评估每月50,000 IU胆钙化醇与安慰剂对HRQOL的影响。使用简短36项健康调查（SF-36）收集基线及6个月后的HRQOL数据。采用线性回归分析比较维生素D组和安慰剂组随时间推移HRQOL的变化。
187/275（68%）完成了基线和随访的SF-36并纳入分析。与安慰剂组相比，干预组血清25-羟维生素D中位数几乎翻倍（分别为58.5 - 106.0 nmol/L和60.0 - 61.5 nmol/L）。在SF-36领域因身体问题导致的角色限制方面，两组之间存在微小但显著的差异（调整后B：-8.90；95% CI：-17.16至-0.65），维生素D组处于劣势。
对于接受口服抗糖尿病治疗的非维生素D缺乏的2型DM患者，补充6个月维生素D并未改善HRQOL。
